Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Positive Effects of Promoting Physical Activity and Balanced Diets in a Primary School Setting with a High Proportion of Migrant School Children.

Weber KS, Spörkel O, Mertens M, Freese A, Strassburger K, Kemper B, Bachmann C, Diehlmann K, Stemper T, Buyken AE, Ketelhut K, Müssig K.

Exp Clin Endocrinol Diabetes. 2017 Sep;125(8):554-562. doi: 10.1055/s-0043-101918. Epub 2017 Sep 19.

PMID:
28926856
2.

Efficacy of Liposomal Bupivacaine Infiltration on the Management of Total Knee Arthroplasty.

Sakamoto B, Keiser S, Meldrum R, Harker G, Freese A.

JAMA Surg. 2017 Jan 1;152(1):90-95. doi: 10.1001/jamasurg.2016.3474.

3.

Testing for HIV during pregnancy: 5 years after changing German pregnancy guidelines.

Pauly F, Freese AL, Golic M, Henrich W, Weizsaecker K.

Arch Gynecol Obstet. 2013 Jul;288(1):29-32. doi: 10.1007/s00404-013-2744-9. Epub 2013 Feb 6.

PMID:
23385348
4.

Long-term follow-up after gene therapy for canavan disease.

Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, Wang DJ, Assadi M, Goldfarb O, Goldman HW, Freese A, Young D, During MJ, Samulski RJ, Janson CG.

Sci Transl Med. 2012 Dec 19;4(165):165ra163. doi: 10.1126/scitranslmed.3003454.

5.

Genetic low nephron number hypertension is associated with altered expression of osteopontin and CD44 during nephrogenesis.

Freese A, Wehland M, Freese F, Bamberg C, Kreutz R, Rothermund L.

J Perinat Med. 2013 May;41(3):295-9. doi: 10.1515/jpm-2012-0178.

PMID:
23241663
6.

Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG.

J Neurooncol. 2007 Nov;85(2):133-48. Epub 2007 Sep 15.

7.

Efficacy of nonviral gene transfer in the canine brain.

Oh S, Pluhar GE, McNeil EA, Kroeger KM, Liu C, Castro MG, Lowenstein PR, Freese A, Ohlfest JR.

J Neurosurg. 2007 Jul;107(1):136-44.

8.

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.

Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, Moore P, Palmer D, Ng P, Young JD, Lowenstein PR, Castro MG.

Neuro Oncol. 2007 Jul;9(3):245-58. Epub 2007 May 23.

9.

Adenoviral-mediated gene transfer into the canine brain in vivo.

Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, Curtin JF, McNiel EA, Freese AB, Ohlfest JR, Moore P, Lowenstein PR, Castro MG.

Neurosurgery. 2007 Jan;60(1):167-77; discussion 178.

10.

Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.

Janson CG, McPhee SW, Francis J, Shera D, Assadi M, Freese A, Hurh P, Haselgrove J, Wang DJ, Bilaniuk L, Leone P.

Neuropediatrics. 2006 Aug;37(4):209-21.

PMID:
17177147
11.

Immune responses to AAV in a phase I study for Canavan disease.

McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, Shera D, Lioutermann L, Feely M, Freese A, Leone P.

J Gene Med. 2006 May;8(5):577-88.

PMID:
16532510
12.

Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies.

Ohlfest JR, Freese AB, Largaespada DA.

Curr Gene Ther. 2005 Dec;5(6):629-41. Review.

PMID:
16457652
13.

Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.

Janson CG, Kolodny EH, Zeng BJ, Raghavan S, Pastores G, Torres P, Assadi M, McPhee S, Goldfarb O, Saslow B, Freese A, Wang DJ, Bilaniuk L, Shera D, Leone P.

Ann Neurol. 2006 Feb;59(2):428-31.

PMID:
16437572
14.

Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies.

Wiesner SM, Freese A, Ohlfest JR.

Neurosurg Focus. 2005 Oct 15;19(4):E3. Review.

PMID:
16241105
15.

Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma.

Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Saplis RJ, Ekker SC, Low WC, Freese AB, Largaespada DA.

Mol Ther. 2005 Nov;12(5):778-88. Epub 2005 Sep 16.

16.

Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.

McPhee SW, Francis J, Janson CG, Serikawa T, Hyland K, Ong EO, Raghavan SS, Freese A, Leone P.

Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):112-21.

PMID:
15857674
17.

Effect of altering titer, serotype, and promoter in recombinant adenoassociate virus gene therapy expression of spinal cord neurons and astrocytes.

Harrop JS, Poulsen DJ, Xiao W, Freese A, During MJ.

Spine (Phila Pa 1976). 2004 Dec 15;29(24):2787-92.

PMID:
15599280
18.

Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.

Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, Wang DJ, Shera D, Hurh P, Rupin J, Saslow E, Goldfarb O, Goldberg M, Larijani G, Sharrar W, Liouterman L, Camp A, Kolodny E, Samulski J, Leone P.

Hum Gene Ther. 2002 Jul 20;13(11):1391-412.

PMID:
12162821
20.

Viral-based gene transfer to the mammalian CNS for functional genomic studies.

Janson CG, McPhee SW, Leone P, Freese A, During MJ.

Trends Neurosci. 2001 Dec;24(12):706-12. Review. Erratum in: Trends Neurosci 2002 Jan;25(1):59.

PMID:
11718875
21.

Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease.

Leone P, Janson CG, Bilaniuk L, Wang Z, Sorgi F, Huang L, Matalon R, Kaul R, Zeng Z, Freese A, McPhee SW, Mee E, During MJ.

Ann Neurol. 2000 Jul;48(1):27-38. Erratum in: Ann Neurol 2000 Sep;48(3):398. Bilianuk L [corrected to Bilaniuk L].

PMID:
10894213
22.
23.

Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats.

Leone P, McPhee SW, Janson CG, Davidson BL, Freese A, During MJ.

Neuroreport. 2000 Apr 27;11(6):1145-51.

PMID:
10817582
24.

Restorative gene therapy approaches to Parkinson's disease.

Freese A.

Med Clin North Am. 1999 Mar;83(2):537-48. Review.

PMID:
10093593
25.

In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.

During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth RH, Sladek JR Jr, O'Malley KL, Redmond DE Jr.

Gene Ther. 1998 Jun;5(6):820-7.

26.

Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: prospects for gene therapy in epilepsy.

O'Connor WM, Davidson BL, Kaplitt MG, Abbey MV, During MJ, Leone P, Langer D, O'Connor MJ, Freese A.

Exp Neurol. 1997 Nov;148(1):167-78.

PMID:
9398459
27.

Analysis of harvest morbidity and radiographic outcome using autograft for anterior cervical fusion.

Schnee CL, Freese A, Weil RJ, Marcotte PJ.

Spine (Phila Pa 1976). 1997 Oct 1;22(19):2222-7.

PMID:
9346142
28.

Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy.

Freese A, Kaplitt MG, O'Connor WM, Abbey M, Langer D, Leone P, O'Connor MJ, During MJ.

Epilepsia. 1997 Jul;38(7):759-66.

29.

Parkinson's disease: the case for novel treatment strategies.

Stern MB, Freese A.

Exp Neurol. 1997 Mar;144(1):2-3.

PMID:
9126142
30.

Functional and biosynthetic aspects of sialic acid diversity.

Schauer R, de Freese A, Gollub M, Iwersen M, Kelm S, Reuter G, Schlenzka W, Vandamme-Feldhaus V, Shaw L.

Indian J Biochem Biophys. 1997 Feb-Apr;34(1-2):131-41.

PMID:
9343941
31.

MR of thoracic cord compression caused by epidural extramedullary hematopoiesis in myelodysplastic syndrome.

Dibbern DA Jr, Loevner LA, Lieberman AP, Salhany KE, Freese A, Marcotte PJ.

AJNR Am J Neuroradiol. 1997 Feb;18(2):363-6.

33.
34.

Prospects for gene therapy in Parkinson's disease.

Freese A, Stern M, Kaplitt MG, O'Connor WM, Abbey MV, O'Connor MJ, During MJ.

Mov Disord. 1996 Sep;11(5):469-88. Review.

PMID:
8866488
35.

Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release.

Freese A, During MJ, Davidson BL, Gennarelli TA, Kaplitt MG, Flamm ES, Snyder PJ.

J Clin Endocrinol Metab. 1996 Jun;81(6):2401-4.

PMID:
8964885
36.

Subvocal speech, reading rate, and comprehension.

Freese AR.

Percept Mot Skills. 1996 Jun;82(3 Pt 2):1343-68.

PMID:
8823900
37.

Hippocampal cell distributions in temporal lobe epilepsy: a comparison between patients with and without an early risk factor.

O'Connor WM, Masukawa L, Freese A, Sperling MR, French JA, O'Connor MJ.

Epilepsia. 1996 May;37(5):440-9.

PMID:
8617172
38.

Determination of HLA-B7 T-cell epitopes.

Freese A, Zavazava N.

Transpl Int. 1996;9 Suppl 1:S352-5.

PMID:
8959863
39.

Rat MHC class I peptides are immunogenic.

Zavazava N, Fandrich F, Ott KA, Freese A, Turnewitsch K.

Transpl Int. 1996;9 Suppl 1:S337-9.

PMID:
8959859
40.

Recognition of HLA-derived peptides in transplant patients.

Zavazava N, Stegmann S, Freese A, Müller-Ruchholtz W.

Transplant Proc. 1995 Feb;27(1):489-90. No abstract available.

PMID:
7879072
41.
42.

The application of 5-bromodeoxyuridine in the management of CNS tumors.

Freese A, O'Rourke D, Judy K, O'Connor MJ.

J Neurooncol. 1994;20(1):81-95. Review.

PMID:
7807187
43.

Superficial siderosis of the central nervous system: magnetic resonance imaging and pathological correlation. Case report.

Janss AJ, Galetta SL, Freese A, Raps EC, Curtis MT, Grossman RI, Gomori JM, Duhaime AC.

J Neurosurg. 1993 Nov;79(5):756-60.

PMID:
8410256
44.
45.

Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity.

Freese A, Finklestein SP, DiFiglia M.

Brain Res. 1992 Mar 20;575(2):351-5.

PMID:
1349256
46.

Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes.

During MJ, Freese A, Deutch AY, Kibat PG, Sabel BA, Langer R, Roth RH.

Exp Neurol. 1992 Feb;115(2):193-9.

PMID:
1735466
47.
48.

Indolic and kynurenine pathway metabolites of tryptophan in rat brain: effect of precursor availability on in vivo release.

During MJ, Heyes MP, Freese A, Swartz KJ, Matson WR, Markey SP, Martin JB, Roth RH.

Adv Exp Med Biol. 1991;294:535-9. No abstract available.

PMID:
1837690
49.

HSV-1 vector mediated neuronal gene delivery. Strategies for molecular neuroscience and neurology.

Freese A, Geller AI, Neve R.

Biochem Pharmacol. 1990 Nov 15;40(10):2189-99. No abstract available.

PMID:
2173924
50.

Extended levodopa release from a subcutaneously implanted polymer matrix in rats.

Sabel BA, Dominiak P, Hüaser W, During MJ, Freese A.

Ann Neurol. 1990 Nov;28(5):714-7.

PMID:
2260860

Supplemental Content

Loading ...
Support Center